Meag Munich Ergo Kapitalanlagegesellschaft MBH purchased a new position in Eli Lilly and Company (NYSE:LLY) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 137,583 shares of the company’s stock, valued at approximately $11,731,000.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Accredited Investors Inc. raised its holdings in Eli Lilly and by 0.4% in the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after acquiring an additional 14 shares during the last quarter. Northwest Quadrant Wealth Management LLC raised its holdings in Eli Lilly and by 0.5% in the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after acquiring an additional 19 shares during the last quarter. Oakworth Capital Inc. raised its holdings in Eli Lilly and by 0.3% in the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after acquiring an additional 20 shares during the last quarter. Sfmg LLC raised its holdings in Eli Lilly and by 0.5% in the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after acquiring an additional 20 shares during the last quarter. Finally, Jackson Grant Investment Advisers Inc. raised its holdings in Eli Lilly and by 0.7% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after acquiring an additional 24 shares during the last quarter. 76.42% of the stock is currently owned by hedge funds and other institutional investors.

In other news, major shareholder Lilly Endowment Inc sold 195,000 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $85.14, for a total transaction of $16,602,300.00. Following the completion of the sale, the insider now owns 123,513,247 shares of the company’s stock, valued at approximately $10,515,917,849.58. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 651,088 shares of company stock valued at $56,439,586. Company insiders own 0.20% of the company’s stock.

Shares of Eli Lilly and Company (NYSE:LLY) opened at $86.54 on Friday. The firm has a market cap of $95,321.79, a price-to-earnings ratio of 21.17, a price-to-earnings-growth ratio of 1.76 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Company has a 12 month low of $71.76 and a 12 month high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.88 EPS. equities research analysts predict that Eli Lilly and Company will post 4.22 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. The ex-dividend date is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a yield of 2.60%. Eli Lilly and’s payout ratio is currently 98.58%.

A number of equities analysts recently weighed in on LLY shares. BidaskClub lowered shares of Eli Lilly and from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Jefferies Group restated a “buy” rating and issued a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Leerink Swann restated a “hold” rating on shares of Eli Lilly and in a report on Thursday, August 31st. Piper Jaffray Companies restated a “buy” rating and issued a $103.00 price objective on shares of Eli Lilly and in a report on Thursday, August 31st. Finally, BMO Capital Markets restated an “underperform” rating and issued a $71.00 price objective (down from $73.00) on shares of Eli Lilly and in a report on Wednesday, September 6th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company. Eli Lilly and presently has a consensus rating of “Hold” and a consensus price target of $90.25.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/meag-munich-ergo-kapitalanlagegesellschaft-mbh-purchases-shares-of-137583-eli-lilly-and-company-lly/1769470.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.